Publications by authors named "Thuong Nguyen Thuy Thuong"

Article Synopsis
  • Tuberculous meningitis is a serious disease that can cause death or long-term problems for about half of the people it affects.
  • Current treatment methods are based on how we treat lung tuberculosis, but they don't work as well for the brain.
  • Researchers are calling for new global trials with better drugs to improve treatment and help patients with this dangerous infection.
View Article and Find Full Text PDF

Indonesia has the third highest number of tuberculosis (TB) patients infected with Mycobacterium tuberculosis (MTB) Lineage 1 (L1). Most of these MTB L1 cases can be found in Indonesia's remote easternmost province of Papua, one of Indonesia's most underdeveloped provinces with a particularly high burden for TB. In this study, we sequenced and described 42 MTB L1 isolates from a well-characterized cohort of patients.

View Article and Find Full Text PDF
Article Synopsis
  • * A study of 216 adults with TBM utilized brain MRI and clinical data, applying machine learning models to predict disease progression, achieving 60% balanced accuracy in prognosis across six categories.
  • * The model successfully identified TBM-related brain lesions in both HIV-positive and negative patients and accurately tracked disease changes in 80% of cases, showcasing potential for improved patient outcomes through timely clinical intervention.
View Article and Find Full Text PDF
Article Synopsis
  • There is currently no fast and accurate test for diagnosing tuberculous meningitis (TBM), which often delays treatment; this study aimed to create a better diagnostic tool by using a variety of data from past studies across different populations.* -
  • The research involved 3,761 participants from 14 studies, identifying key predictive factors like cerebrospinal fluid glucose and HIV status, and analyzed the data using techniques like logistic regression and random forest regression.* -
  • The resulting mobile app for TBM diagnosis shows promising accuracy, with further validation needed to confirm its effectiveness in diverse clinical settings.*
View Article and Find Full Text PDF

Drug development for tuberculosis is hindered by the methodological limitations in the definitions of patient outcomes, particularly the slow organism growth and difficulty in obtaining suitable and representative samples throughout the treatment. We developed target product profiles for biomarker assays suitable for early-phase and late-phase clinical drug trials by consulting subject-matter experts on the desirable performance and operational characteristics of such assays for monitoring of tuberculosis treatment in drug trials. Minimal and optimal criteria were defined for scope, intended use, pricing, performance, and operational characteristics of the biomarkers.

View Article and Find Full Text PDF
Article Synopsis
  • This study investigates how variations in Mycobacterium tuberculosis (M. tuberculosis) may influence tuberculosis infection and treatment results.
  • A high-throughput method was used on 158 drug-sensitive strains to analyze their genetic and phenotypic relationships, with a focus on their growth under different host-like conditions.
  • Results showed that these strains exhibited diverse growth traits linked to specific genetic mutations, identifying key variants that correlate with clinical outcomes like cavitary disease and treatment failure.
View Article and Find Full Text PDF

Mortality from tuberculous meningitis (TBM) remains around 30%, with most deaths occurring within 2 months of starting treatment. Mortality from drug-resistant strains is higher still, making early detection of drug resistance (DR) essential. Targeted next-generation sequencing (tNGS) produces high read depths, allowing the detection of DR-associated alleles with low frequencies.

View Article and Find Full Text PDF
Article Synopsis
  • Mycobacterium tuberculosis, which causes tuberculosis (TB), can affect various organs, including the brain, leading to a serious condition called TB meningitis (TBM), yet the immune mechanisms behind these differences in disease presentation are not fully understood.
  • Research has shifted focus from T cell responses to the role of antibodies in controlling M. tuberculosis, particularly looking at how these antibodies respond differently in the lungs versus the brain.
  • Using an advanced serology technique, the study analyzed antibody responses in TBM patients compared to those with pulmonary TB, revealing distinct profiles in the cerebrospinal fluid that highlight a unique immune response in TBM, potentially serving as markers for disease severity and prognosis.
View Article and Find Full Text PDF

Background: Tuberculous meningitis (TBM) is difficult to diagnose. We investigated whether a 3-gene host response signature in blood can distinguish TBM from other brain infections.

Methods: The expression of 3 genes (dual specificity phosphatase 3 [DUSP3], guanylate-binding protein [GBP5], krupple-like factor 2 [KLF2]) was analyzed by RNA sequencing of archived whole blood from 4 cohorts of Vietnamese adults: 281 with TBM, 279 with pulmonary tuberculosis, 50 with other brain infections, and 30 healthy controls.

View Article and Find Full Text PDF

Six lineages of Mycobacterium tuberculosis sensu stricto (which excludes M. africanum) are described. Single-country or small observational data suggest differences in clinical phenotype between lineages.

View Article and Find Full Text PDF

Antibiotic tolerance in leads to less effective bacterial killing, poor treatment responses and resistant emergence. Therefore, we investigated the rifampicin tolerance of isolates, with or without pre-existing isoniazid-resistance. We determined the rifampicin survival fraction by minimum duration of killing assay in isoniazid susceptible (IS, n=119) and resistant (IR, n=84) isolates.

View Article and Find Full Text PDF

Background: To improve tuberculosis (TB) diagnosis, the World Health Organisation (WHO) has called for a non-sputum based triage test to focus TB testing on people with a high likelihood of having active pulmonary tuberculosis (TB). Various host or pathogen biomarker-based testing devices are in design stage and require validity assessment. Host biomarkers have shown promise to accurately rule out active TB, but further research is required to determine generalisability.

View Article and Find Full Text PDF

Background: Cellular metabolism is critical for the host immune function against pathogens, and metabolomic analysis may help understand the characteristic immunopathology of tuberculosis. We performed targeted metabolomic analyses in a large cohort of patients with tuberculous meningitis (TBM), the most severe manifestation of tuberculosis, focusing on tryptophan metabolism.

Methods: We studied 1069 Indonesian and Vietnamese adults with TBM (26.

View Article and Find Full Text PDF

Background: Combatting the tuberculosis (TB) epidemic caused by ( ) necessitates a better understanding of the factors contributing to patient clinical outcomes and transmission. While host and environmental factors have been evaluated, the impact of genetic background and phenotypic diversity is underexplored. Previous work has made associations between genetic lineages and some clinical and epidemiological features, but the bacterial traits underlying these connections are largely unknown.

View Article and Find Full Text PDF

Offering patients with tuberculosis (TB) an optimal and timely treatment regimen depends on the rapid detection of Mycobacterium tuberculosis (Mtb) drug resistance from clinical samples. Finding Low Abundance Sequences by Hybridization (FLASH) is a technique that harnesses the efficiency, specificity, and flexibility of the Cas9 enzyme to enrich targeted sequences. Here, we used FLASH to amplify 52 candidate genes probably associated with resistance to first- and second-line drugs in the Mtb reference strain (H37Rv), then detect drug resistance mutations in cultured Mtb isolates, and in sputum samples.

View Article and Find Full Text PDF

Eight lineages of are described. Single-country or small observational data suggest differences in clinical phenotype between lineages. We present strain lineage and clinical phenotype data from 12,246 patients from 3 low-incidence and 5 high-incidence countries.

View Article and Find Full Text PDF

Background: Cellular metabolism is critical for the host immune function against pathogens, and metabolomic analysis may help understand the characteristic immunopathology of tuberculosis. We performed targeted metabolomic analyses in a large cohort of patients with tuberculous meningitis (TBM), the most severe manifestation of tuberculosis, focusing on tryptophan metabolism.

Methods: We studied 1069 Indonesian and Vietnamese adults with TBM (26.

View Article and Find Full Text PDF

Tuberculous meningitis is a devastating brain infection that is caused by Mycobacterium tuberculosis and is notoriously difficult to diagnose and treat. New technologies characterising the transcriptome, proteome, and metabolome have identified new molecules and pathways associated with tuberculous meningitis severity and poor outcomes that could offer novel diagnostic and therapeutic targets. The next-generation GeneXpert MTB/RIF Ultra assay, when used on CSF, offers diagnostic sensitivity for tuberculous meningitis of approximately 70%, although it is not widely available and a negative result cannot rule out tuberculous meningitis.

View Article and Find Full Text PDF

A dysregulated host immune response significantly contributes to morbidity and mortality in tuberculous meningitis (TBM). Effective host directed therapies (HDTs) are critical to improve survival and clinical outcomes. Currently only one HDT, dexamethasone, is proven to improve mortality.

View Article and Find Full Text PDF

Tuberculous meningitis (TBM) is the most lethal form of tuberculosis. The incidence and mortality of TBM is unknown due to diagnostic challenges and limited disaggregated reporting of treated TBM by existing surveillance systems. We aimed to estimate the incidence and mortality of TBM in adults (15+ years) globally.

View Article and Find Full Text PDF

Background: The development of a fast and accurate, non-sputum-based point-of-care triage test for tuberculosis (TB) would have a major impact on combating the TB burden worldwide. A new fingerstick blood test has been developed by Cepheid (the Xpert MTB Host Response [MTB-HR] prototype), which generates a "TB score" based on messenger RNA (mRNA) expression of 3 genes. Here we describe the first prospective findings of the MTB-HR prototype.

View Article and Find Full Text PDF

New tools to monitor treatment response and predict outcome from tuberculous meningitis (TBM) are urgently required. We retrospectively evaluated the 16S rRNA-based molecular bacterial load assay (MBLA) to quantify viable Mycobacterium tuberculosis in serial cerebrospinal fluid (CSF) from adults with TBM. 187 CSF samples were collected before and during the first two months of treatment from 99 adults TBM, comprising 56 definite, 43 probable or possible TBM, and 18 non-TBM and preserved at -80°C prior to MBLA.

View Article and Find Full Text PDF

Adjunctive treatment with antiinflammatory corticosteroids like dexamethasone increases survival in tuberculosis meningitis. Dexamethasone responsiveness associates with a C/T variant in (), which regulates expression of the proinflammatory mediator leukotriene B (LTB). TT homozygotes, with increased expression of , have the highest survival when treated with dexamethasone and the lowest survival without.

View Article and Find Full Text PDF

The pathogenesis of Tuberculous meningitis (TBM) is poorly understood, but contemporary molecular biology technologies have allowed for recent improvements in our understanding of TBM. For instance, neutrophils appear to play a significant role in the immunopathogenesis of TBM, and either a paucity or an excess of inflammation can be detrimental in TBM. Further, severity of HIV-associated immunosuppression is an important determinant of inflammatory response; patients with the advanced immunosuppression (CD4+ T-cell count of <150 cells/μL) having higher CSF neutrophils, greater CSF cytokine concentrations and higher mortality than those with CD4+ T-cell counts > 150 cells/μL.

View Article and Find Full Text PDF